Menu
Search
|

Menu

Close
X

Mirati Therapeutics Inc MRTX.OQ (NASDAQ Stock Exchange Global Select Market)

105.55 USD
-0.16 (-0.15%)
As of 9:00 PM BST
Previous Close 105.71
Open 105.98
Volume 72,294
3m Avg Volume 248,704
Today’s High 107.01
Today’s Low 103.96
52 Week High 109.61
52 Week Low 28.50
Shares Outstanding (mil) 38.13
Market Capitalization (mil) 4,030.63
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.13 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
13
FY17
0
FY16
0
EPS (USD)
FY19
-1.170
FY18
-3.166
FY17
-2.788
FY16
-4.203
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
857.03
11.36
Price to Book (MRQ)
vs sector
13.43
4.28
Price to Cash Flow (TTM)
vs sector
--
23.59
Total Debt to Equity (MRQ)
vs sector
0.00
18.53
LT Debt to Equity (MRQ)
vs sector
0.00
13.28
Return on Investment (TTM)
vs sector
-58.95
12.53
Return on Equity (TTM)
vs sector
-59.15
17.18

EXECUTIVE LEADERSHIP

Faheem Hasnain
Chairman of the Board, Since 2019
Salary: --
Bonus: --
Charles Baum
President, Chief Executive Officer, Director, Since 2012
Salary: $579,700.00
Bonus: --
Jamie Donadio
Chief Financial Officer, Senior Vice President, Since 2016
Salary: $363,000.00
Bonus: --
James Christensen
Executive Vice President, Chief Scientific Officer, Since 2018
Salary: $374,385.00
Bonus: --
Isan Chen
Chief Medical and Development Officer, Executive Vice President, Since 2013
Salary: $420,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9393 Towne Centre Dr Ste 200
SAN DIEGO   CA   92121-3070

Phone: +1858.3323410

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

SPONSORED STORIES